In fiscal 2025, which ended Dec 31, 2025, Intellia Therapeutics, Inc. used $394.7 million of cash from operations, down 13.1% from the year before. It spent $1.1 million on capital expenditures. Free cash flow was negative, at -$395.9 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Depreciation and amortization |
9
-13.7%
|
10
-5.0%
|
10
+14.6%
|
9
+18.5%
|
8
+9.9%
|
7
+9.2%
|
6
+13.0%
|
6
+25.2%
|
4
+49.1%
|
3
+172.2%
|
1
|
| Stock-based compensation |
63
-39.2%
|
80
-48.0%
|
154
+15.1%
|
134
+46.7%
|
91
+94.4%
|
47
+136.2%
|
20
+31.9%
|
15
-11.5%
|
17
+11.3%
|
15
+128.2%
|
7
|
| Operating cash flow |
-355
+13.5%
|
-395
-13.1%
|
-349
+11.5%
|
-394
-18.2%
|
-333
-48.1%
|
-225
-350.9%
|
-50
+51.7%
|
-103
-68.5%
|
-61
+6.2%
|
-65
-280.8%
|
36
|
| Investing | |||||||||||
| Capital expenditures |
3
+46.3%
|
1
-80.5%
|
6
-58.7%
|
14
+3.1%
|
14
+6.3%
|
13
+255.8%
|
4
-47.2%
|
7
+6.9%
|
6
-37.0%
|
10
+63.7%
|
6
|
| Investing cash flow |
14
-96.0%
|
228
+81.6%
|
126
+500.6%
|
-31
-119.6%
|
160
+129.1%
|
-551
-156.8%
|
-214
-952.0%
|
25
+109.7%
|
-261
-2484.3%
|
-10
-63.7%
|
-6
|
| Financing | |||||||||||
| Financing cash flow |
305
+131.5%
|
131
-29.2%
|
186
+42.5%
|
130
-77.6%
|
583
-20.9%
|
737
+98.2%
|
372
+386.4%
|
76
+90.1%
|
40
-71.9%
|
143
-14.5%
|
167
|
| Change in cash | |||||||||||
| Net change in cash |
-36
-148.9%
|
-35
+6.2%
|
-38
+87.3%
|
-295
-172.0%
|
410
+1148.0%
|
-39
-136.4%
|
107
+6687.7%
|
-2
|
—
|
—
|
—
|
| Free cash flow |
-358
+13.2%
|
-396
-11.6%
|
-355
+13.1%
|
-408
-17.7%
|
-347
-45.9%
|
-238
-344.5%
|
-53
+51.4%
|
-110
-62.7%
|
-68
+10.3%
|
-75
-351.7%
|
30
|
| Per share | |||||||||||
| Free cash flow per share |
-2.82
+28.4%
|
-3.65
-1.8%
|
-3.59
+22.0%
|
-4.60
-2.0%
|
-4.51
|
—
|
—
|
—
|
—
|
—
|
—
|
| Ratios | |||||||||||
| Free cash flow margin |
-677.06%
|
-584.98%
|
-612.78%
|
-1,124.94%
|
-665.46%
|
-719.41%
|
-92.25%
|
-255.28%
|
-222.17%
|
—
|
—
|
| Capital expenditures to revenue |
5.49%
|
1.67%
|
9.98%
|
38.55%
|
26.01%
|
38.59%
|
6.18%
|
15.76%
|
20.89%
|
—
|
—
|
| Stock-based compensation to revenue |
118.53%
|
118.54%
|
266.55%
|
369.54%
|
175.36%
|
142.22%
|
34.32%
|
35.01%
|
56.01%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NTLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1652130
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.